CML - imatinib

In order to better understand the mechanism of the chimeric BCR-ABL protein, scientists used other oncoproteins and tumor viruses. For example, the first work involving oncogenic protein kinases revolved around the Rous sarcoma virus oncogene product (v-Src). The Src protein was shown to have highly similar negative regulatory mechanisms to that of Abl. This includes the SH2 and SH3 domains which inhibit kinase activity in both proteins. Both proteins use myristates as well as intramolecular interactions between the SH3, SH2 and kinase domain to inactivate kinase activity. By 1990, sequencing of the BCR-ABL protein allowed scientistsp to categorize the domain structure of c-ABL as well as the BCR-ABL product.